Research and Development Achievement: University-developed rotary tablet press secures millions in funding

Recently, the "Smart Modular Rotary Tablet Press" jointly developed by a domestic university and a biopharmaceutical group has announced the completion of tens of millions of yuan in Pre-A round financing, led by Sequoia China and Qiming Venture Partners. This domestically produced equipment, which breaks the foreign technological monopoly, marks a significant leap in the transformation of scientific research achievements in China's pharmaceutical equipment field, entering the fast track from "the lab to the production line" with its core technologies such as "1-minute rapid mold change" and "AI adaptive tablet pressing."

Tech Breakthrough: Targeting Industry Pain Points, Redefining Production Standards

Traditional tablet presses have long relied on imports, facing issues such as lengthy mold changes, high energy consumption, and insufficient flexible production. Professor Zhang's team from the Mechanical Engineering College of XX University has spent 5 years working on this, achieving breakthroughs in three core technologies.

1. Maglev Axle-Free Drive System: Ditching the traditional gearbox, the system rotates the turntable using electromagnetic force, reducing the mold change time from 4 hours to 1 minute, and lowering the energy consumption during equipment startup by 70%.
2. AI Vision-Based Seamless Control: Integrating 12 industrial cameras and deep learning algorithms, it monitors 20 indicators including tablet weight, hardness, disintegration time, etc., in real-time, improving the pass rate to 99.9%.
3. Modular Intelligent Platform: Utilizing "Lego-style" functional module design, supports one-click switching between tablet, capsule, and oral film dosage forms, boosting equipment utilization from 65% to 95%.

Industry-Academia-Research Collaboration: Lab Achievements "Race" onto Production Lines

"Academic research cannot end with papers; it must address real issues," said Professor Li, the chief scientist of the project. In the early stages of development, the team collaborated with a leading pharmaceutical company to establish a "Joint Laboratory," transforming pain points in the production line into research topics:

• In response to the problem of sticking in traditional Chinese medicine extract, we have developed a "microporous ceramic coated mold" that reduces the adhesion rate of materials by 90%.
• In response to the demand for preventing cross-contamination in highly active drugs, we have pioneered a dual-mode system of "negative pressure isolation + UV sterilization," reducing the clean verification time by 80%.

Currently, the equipment has completed industrial validation in 5 pharmaceutical companies, doubling the annual production capacity of a single production line and reducing comprehensive costs by 35%. A production director of a listed pharmaceutical company commented, "In the past, a single shutdown for maintenance of imported equipment resulted in losses exceeding a million. Now, the domestic equipment's stability fully meets standards, and the service response is 10 times faster."

Capital Empowerment: Accelerating Domestic Replacement Process

This round of financing will be allocated to three main areas:

1. Capacity Expansion: Constructing an intelligent factory in Suzhou with an annual production capacity of 500 units to meet the explosive market demand.
2. Tech Iteration: Developing a "Cloud-based Slicing Brain" based on Digital Twin technology for global remote equipment maintenance and operation.
3. Building an Ecosystem: Collaborating with upstream and downstream enterprises to create a "modular tabletting ecosystem," promoting the establishment of industry standards.

Sequoia China Partner states, "What we value is not only the technological barrier, but also the team's ability to transform 'papers into production lines.' This equipment has the potential to rewrite the global tablet press market landscape."

Industry Outlook: The Leap from "Following" to "Leading"

Data shows that the market size of tablet presses in our country exceeds 100 billion yuan, with 80% of the high-end market relying on imports. As the "Made in China 2025" policy advances, domestically produced equipment is entering a golden window of opportunity.

The China Pharmaceutical Equipment Engineering Association expert noted: "The success of this project has provided the 'XX Model' for the transformation of scientific research achievements in universities — feeding back corporate needs into research directions and using capital leverage to accelerate industrialization. In the next three years, we may witness more 'national heavy-duty equipment' transition from laboratories to production lines."

Conclusion

As the transformation of scientific research achievements moves beyond mere theory, and as the wisdom of universities deeply collides with industrial demands, the funding story of this rotary tablet press is vividly illustrating the independent innovation in China's pharmaceutical equipment field. Driven by policies, capital, and technology, Chinese pharmaceutical companies are closer than ever to the dream of "using domestically produced equipment that matches the world's standards."